Isatin-based oxime ethers as anticancer agents against human colorectal carcinoma.

Shashikala Mariswamy Rajesh, Priyadarshini A N, Vinay Kumar D C, Sudhanva Muddenahalli Srinivasa, Toreshettahally R Swaroop, Rajaghatta N Suresh, Shobith Rangappa, Kanchugarakoppal S Rangappa

Abstract read

PubMed Publisher

In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shashikala Mariswamy RajeshDepartment of Studies in Chemistry, University of Mysore, Manasagangotri, Mysuru, Karnataka, 570 006, India.

Priyadarshini A NAdichunchanagiri Institute for Molecular Medicine, Adichunchanagiri Institute of Medical Sciences, Adichunchanagiri University, BG Nagara, Karnataka, 571 448, India.

Vinay Kumar D CDepartment of Physics, The National Institute of Engineering, Mysuru, 570 008, Karnataka, India.

Sudhanva Muddenahalli SrinivasaAdichunchanagiri Institute for Molecular Medicine, Adichunchanagiri Institute of Medical Sciences, Adichunchanagiri University, BG Nagara, Karnataka, 571 448, India.

Toreshettahally R SwaroopDepartment of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysuru, Karnataka, 570 006, India.

Rajaghatta N SureshDepartment of Materials Science, University With Potential for Excellence, University of Mysore, Manasagangotri, Mysuru, Karnataka, 570 006, India.

Shobith RangappaAdichunchanagiri Institute for Molecular Medicine, Adichunchanagiri Institute of Medical Sciences, Adichunchanagiri University, BG Nagara, Karnataka, 571 448, India. aimm@acu.edu.in.

Kanchugarakoppal S RangappaVijnana Bhavan, University of Mysore, Manasagangotri, Mysuru, Karnataka, 570 006, India. rangappaks@ioe.uni-mysore.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is one of the leading causes of cancer-related deaths and ranks third among them. Our efforts to develop new anticancer agents to treat this disease resulted in the synthesis of new isatin-based oxime ethers. The cytotoxic effects of these compounds against HCT116 were analyzed using MTT and Trypan Blue dye exclusion assays. A compound 10d has emerged as a lead compound with IC

Indexed as

Antineoplastic AgentsColorectal NeoplasmsEthersIsatinOximesCell MovementCell SurvivalHCT116 CellsHEK293 CellsHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsEthersIsatinOximesAnticancerColorectal cancerIsatinOxime etherTriazole

Identifiers

PMID42384169

DOI10.1016/j.ejmech.2019.111700

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.